A new analysis from the Partnership for Safe Medicines (PSM) illustrates the scale of the unregulated market forming around retatrutide before the medicine has completed clinical development or received regulatory approval. Reviewing May and June 2026 import records, PSM identified eight shipments associated with retatrutide. One shipment declared 222,930 pieces.
That figure is a shipment declaration, not a count of verified doses and not evidence that the cargo contained pharmaceutical-grade retatrutide. PSM says its review used FDA import records, ITACS manifest data, FDA registration databases, and product classifications to identify shipments whose descriptions, manufacturers, or addresses appeared inconsistent with legitimate pharmaceutical production. The report does not independently establish the identity, purity, sterility, or concentration of the products in the shipment.
What the report can—and cannot—show
PSM reviewed 167 peptide shipments and 1,792 shipments associated with antidiabetic medicines, semaglutide, and tirzepatide. Among the peptide shipments, 23% originated from facilities the organization identified as illegitimate manufacturers, while 4% were refused entry. PSM also described shipments associated with addresses that appeared to be retail or non-manufacturing locations, including two linked to a Shoppers Drug Mart address.
These findings are a supply-chain warning, not a clinical study. They cannot tell a patient whether a vial labelled “retatrutide” contains retatrutide, another compound, an incorrect amount, or contaminants. They also cannot establish the safety or effectiveness of products sold outside Eli Lilly-sponsored trials. The FDA warns that unapproved GLP-1 products may have uncertain ingredients and quality; retatrutide remains investigational.
Canadian implications
Although PSM’s analysis focuses on U.S. import data, the report has direct relevance for Canadians. A shipment routed through the U.S. or described in a customs record does not create a lawful Canadian supply, and a large declared quantity does not make an online seller legitimate. Health Canada has not approved retatrutide, and there is no authorized retail product for patients to buy in Canada.
For Canadians, legitimate access remains limited to participation in an authorized clinical trial or, in exceptional circumstances, a physician-led request through Health Canada’s Special Access Programme. Anyone who encounters a suspected illegal product can report it through Health Canada’s Health Product Complaint and Incident Reporting system. Do not inject or reconstitute a product based on a shipping label, vendor claim, or social-media recommendation.
Sources
- Partnership for Safe Medicines: Over 200,000 units of retatrutide: May & June 2026 freight fraud (August 28, 2026)
- FDA: FDA’s concerns with unapproved GLP-1 drugs used for weight loss
- Health Canada: Special Access Programme
Disclaimer: GetRetatrutide.ca is an independent educational resource. This article does not constitute medical advice. Retatrutide is not approved by Health Canada or the FDA.